Keeren Shah - Rasna Therapeutics F Director
| RASP Stock | USD 0 0 900.00% |
Insider
Keeren Shah is F Director of Rasna Therapeutics
| Age | 46 |
| Phone | 646 396 4087 |
| Web | https://www.rasna.com |
Rasna Therapeutics Management Efficiency
The company has return on total asset (ROA) of (3.6957) % which means that it has lost $3.6957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9359) %, meaning that it created substantial loss on money invested by shareholders. Rasna Therapeutics' management efficiency ratios could be used to measure how well Rasna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | INSIDER Age | ||
| James Lorimer | DATA Communications Management | N/A | |
| Richard Kellam | DATA Communications Management | 57 | |
| Steve Livingstone | DATA Communications Management | N/A | |
| Christopher Jones | Odyssey Marine Exploration | 50 | |
| Sharad Verma | DATA Communications Management | N/A | |
| Shelly Anwyll | DATA Communications Management | N/A | |
| Rahul Sharma | Odyssey Marine Exploration | N/A | |
| Barbara FranovicWilkins | DATA Communications Management | N/A | |
| Genevieve Gravel | DATA Communications Management | N/A | |
| Christine Custodio | DATA Communications Management | N/A | |
Management Performance
| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 |
Rasna Therapeutics Leadership Team
Elected by the shareholders, the Rasna Therapeutics' board of directors comprises two types of representatives: Rasna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rasna. The board's role is to monitor Rasna Therapeutics' management team and ensure that shareholders' interests are well served. Rasna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rasna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keeren Shah, F Director | ||
| Willy Simon, Ex Chairman |
Rasna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rasna Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 771.81 M | |||
| Shares Owned By Insiders | 85.10 % | |||
| Price To Book | 0.31 X | |||
| EBITDA | 254.41 K | |||
| Net Income | (686.59 K) | |||
| Cash And Equivalents | 10.52 K | |||
| Total Debt | 91.97 K |
Pair Trading with Rasna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rasna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rasna Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Rasna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rasna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rasna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rasna Therapeutics to buy it.
The correlation of Rasna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rasna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rasna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rasna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.